Company intelligence / Profile preview

Nanogen Pharmaceutical Biotechnology

Ho Chi Minh City, Vietnam

Ownership: Private
Development stage: Other

Overview

Nanogen has multiple approved biosimilars in Vietnam including Epoetin alfa, Peginterferon alfa-2a, Interferon-alpha-2a, Peginterferon alfa-2b, and Etanercept. The company completed Phase 3 trials for Nanocovax (COVID-19 vaccine) with 13,000 participants and Phase 1/2 data showing safety and robust immune responses. Phase 3 studies for Darbepoetin alfa and Trastuzumab biosimilars are active.

Therapeutic areas: NephrologyImmunologyInfectious DiseasesHematologyOncology
Modalities: BiosimilarMonoclonal antibodyRecombinant proteinCytokineHormoneVaccineSmall molecule
Industry: Biotech

Partnerships

Coalition for Epidemic Preparedness Innovations

Beyond the preview

Go deeper on Nanogen Pharmaceutical Biotechnology.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Nanogen Pharmaceutical Biotechnology.

Explore the full profile